NLRP3 inhibitor

AC Immune Advances NLRP3 Inhibitor ACI-19764 in Phase 1

LAUSANNE, Switzerland, August 20, 2026 AC Immune SA announced positive preliminary Phase 1 clinical data for ACI-19764, its wholly...

By cGxPwire Editor
August 21, 2026

Bio-Pharma

Neumora Therapeutics Announces Positive NMRA-215 Toxicology Findings

WATERTOWN, Mass., July 27, 2026 Neumora Therapeutics announced positive preclinical toxicology results for NMRA-215, its investigational brain-penetrant oral NLRP3...

By cGxPwire Editor
July 28, 2026

Bio-Pharma

Insilico Medicine Reports First Human Dosing of ISM8969

HONG KONG, June 18, 2026 Insilico Medicine, a clinical-stage biotechnology company powered by generative artificial intelligence (AI), has announced...